Rapid MLS

The iSchemaview Rapid MLS device serves as an AI/ML-driven software system engineered to assist clinicians by quantitatively and visually analyzing non-contrast CT images for brain midline shift detection. It employs advanced artificial intelligence and machine learning algorithms to process NCCT scans, precisely measuring the difference between the expected and actual brain midline, and has demonstrated performance non-inferior to expert measurements, supporting its role in augmenting clinical insights.

The iSchemaview Inc.'s Rapid MLS device, a Class II medical image management and processing system, has received premarket notification clearance from a regulatory body, deeming it substantially equivalent to the iSchemaview Rapid RV/LV. This clearance allows the company to market the device, identified by product code QIH, while upholding continuous obligations such as annual registration, device listing, adherence to good manufacturing practices, and compliance with labeling, misbranding, adulteration, Quality System regulation, and Unique Device Identification (UDI) system rules. The Rapid MLS functions as an AI/ML-driven software designed to analyze non-contrast CT (NCCT) images for measuring brain midline shift, providing both a visual output with a color overlay indicating midline deviation and a quantitative measurement in a text file. While it delivers annotated images, its outputs are not intended for standalone clinical decision-making. Performance validation, conducted with 153 NCCT cases, demonstrated a mean absolute error (MAE) of 0.7 mm, which was confirmed to be non-inferior to the average expert pairwise MAE of 1.0 mm, thereby affirming its comparability and substantial equivalence to the predicate device.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What are the specific clinical scenarios or patient populations where the Rapid MLS device is most beneficial for detecting midline shift?; How does the AI/ML algorithm within Rapid MLS handle variations in image quality, artifacts, or atypical brain pathologies that might affect midline shift measurement?; What is the long-term clinical impact or outcome data for patients whose treatment decisions are informed, but not solely based, on Rapid MLS outputs?; Could the performance of Rapid MLS be further improved by integrating it with other imaging modalities or clinical data, and how might that affect its regulatory classification?; What are the specific characteristics of the 'expert pairwise MAE' and how was the expert consensus established and verified for comparison with the device's performance?